| Characterization of classical and nonclassical Fabry disease: a multicenter study M Arends, C Wanner, D Hughes, A Mehta, D Oder, OT Watkinson, ... Journal of the American Society of Nephrology 28 (5), 1631-1641, 2017 | 352 | 2017 |
| Malignancies and monoclonal gammopathy in G aucher disease; a systematic review of the literature M Arends, L van Dussen, M Biegstraaten, CEM Hollak British journal of haematology 161 (6), 832-842, 2013 | 144 | 2013 |
| Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study M Arends, M Biegstraaten, C Wanner, S Sirrs, A Mehta, PM Elliott, D Oder, ... Journal of medical genetics 55 (5), 351-358, 2018 | 107 | 2018 |
| Quality of life in patients with Fabry disease: a systematic review of the literature M Arends, CEM Hollak, M Biegstraaten Orphanet journal of rare diseases 10, 1-10, 2015 | 103 | 2015 |
| Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors M Arends, M Biegstraaten, DA Hughes, A Mehta, PM Elliott, D Oder, ... PloS one 12 (8), e0182379, 2017 | 99 | 2017 |
| Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease M Arends, FA Wijburg, C Wanner, FM Vaz, ABP van Kuilenburg, ... Molecular Genetics and Metabolism 121 (2), 157-161, 2017 | 72 | 2017 |
| Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study M Arends, S Körver, DA Hughes, A Mehta, CEM Hollak, M Biegstraaten Journal of Inherited Metabolic Disease: Official Journal of the Society for …, 2018 | 37 | 2018 |
| Adaptive pathway development for Fabry disease: a clinical approach Y Schuller, M Arends, S Körver, M Langeveld, CEM Hollak Drug Discovery Today 23 (6), 1251-1257, 2018 | 16 | 2018 |
| Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort M Arends, GE Linthorst, CE Hollak, M Biegstraaten Molecular genetics and metabolism 117 (2), 194-198, 2016 | 11 | 2016 |
| Enzyme replacement therapy in Fabry disease, towards individualized treatment M Arends Universiteit van Amsterdam, 2017 | 1 | 2017 |
| Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study CE Hollak, M Arends, C Wanner, S Sirrs, A Mehta, P Elliott, D Oder, ... Molecular Genetics and Metabolism 123 (2), S64-S65, 2018 | | 2018 |
| Léčba Fabryho choroby–agalsidáza alfa versus agalsidáza beta, mezinárodní studie M Arends, M Biegstraaten, C Wanner | | |
